Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the optimal duration of anticoagulation
therapy (6 months versus 18 months) with direct oral anticoagulant (DOAC) for
cancer-associated low-risk pulmonary embolism patients. The major secondary purpose of this
study is to investigate whether home treatment of cancer-associated low-risk pulmonary
embolism patients with rivaroxaban is feasible, effective, and safe through an observational
management study.